ArticleBMC cancer2026
Optimizing ribociclib dosing in breast cancer with brain metastasis patients using a physiologically based pharmacokinetic model.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to determine the optimal dosing strategy for ribociclib (RIB) in patients with breast cancer and brain metastasis (BCBM) by using a developed and validated physiologically based pharmacokinetic (PBPK) model.
methodsA population PBPK model for RIB was established by integrating its physicochemical properties, pharmacokinetic (PK) data, cyclin-dependent kinase 4/6 (CDK4/6) occupancy profiles, and the physiological characteristics of the BCBM population. The predictive performance of the PBPK model was verified against data from two clinical plasma PK studies and two cerebrospinal fluid (CSF) PK studies.
resultsThe PBPK model demonstrated concordance with observed clinical data. All predicted-to-observed ratios for plasma AUC, Cmax, Cmin, and RIB concentrations in CSF fell within the acceptable 2-fold range (0.5–2.0), with only one exception of 0.43. Furthermore, the model predicted the CSF-to-plasma unbound concentration ratio (Kp, uu), with values closely aligning with clinical observations (400 mg: predicted 0.99 vs. observed 1.22; 600 mg: predicted 1.03 vs. observed 1.29; 900 mg: predicted 1.10 vs. mean observed 1.63). The PBPK model identified CYP3A4/FMO3 (Flavin-containing monooxygenase 3) concentrations, ABCB1 expression, and plasma albumin levels as key physiological parameters governing intracranial Cmin and CDK4/6 occupancy. Based on these simulations, a regimen of 300 mg twice daily (BID) was identified as the optimal dosing strategy for RIB in BCBM patients, with > 90% mean intracranial CDK4/6 occupancy and safety mean Cmin threshold.
conclusionThis study successfully developed and applied a population PBPK model to simulate the PK and pharmacodynamic profiles of RIB. The model proved to be a robust tool for identifying a rational, optimized dosing regimen specifically for BCBM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.